Skip to Main Content
Table 5.

Prognostic factors selected for time to metastases and DSS by multivariate Cox regression

FactorTime to metastases
DSS
Hazard ratio (95% CI)PHazard ratio (95% CI)P
Model A with PCR as combined variable (n = 105)     
    PCR7.3 (2.9-18) <0.001 22.6 (6.9-74) <0.001 
    Largest tumor diameter 2.6 (1.04-6.5) 0.041 4.7 (1.3-17) 0.020 
    Karnofsky performance status   6.0 (1.2-30) 0.029 
    Age   1.03 (0.9-1.1) 0.081 
Model B with tyrosinase and MelanA/MART1 as separate variables (n = 95)     
    Tyrosinase 5.3 (1.7-17) 0.005 5.1 (1.2-21) 0.024 
    MelanA/MART1 9.9 (2.9-34) <0.001 35.9 (5.5-198) <0.001 
    Largest tumor diameter 3.8 (1.2-12) 0.019 10.0 (1.6-63) 0.014 
    Karnofsky performance status   6.7 (1.3-33) 0.021 
Model C with PCR as combined variable (n = 75)     
    PCR14.6 (3-70) 0.001 134.0 (9-1,999) <0.001 
    Largest tumor diameter 6.2 (1.2-34) 0.033 8.1 (0.8-79) 0.072 
    Karnofsky performance status   25.0 (1.6-333) 0.022 
    Sex   6.7 (0.7-50) 0.082 
FactorTime to metastases
DSS
Hazard ratio (95% CI)PHazard ratio (95% CI)P
Model A with PCR as combined variable (n = 105)     
    PCR7.3 (2.9-18) <0.001 22.6 (6.9-74) <0.001 
    Largest tumor diameter 2.6 (1.04-6.5) 0.041 4.7 (1.3-17) 0.020 
    Karnofsky performance status   6.0 (1.2-30) 0.029 
    Age   1.03 (0.9-1.1) 0.081 
Model B with tyrosinase and MelanA/MART1 as separate variables (n = 95)     
    Tyrosinase 5.3 (1.7-17) 0.005 5.1 (1.2-21) 0.024 
    MelanA/MART1 9.9 (2.9-34) <0.001 35.9 (5.5-198) <0.001 
    Largest tumor diameter 3.8 (1.2-12) 0.019 10.0 (1.6-63) 0.014 
    Karnofsky performance status   6.7 (1.3-33) 0.021 
Model C with PCR as combined variable (n = 75)     
    PCR14.6 (3-70) 0.001 134.0 (9-1,999) <0.001 
    Largest tumor diameter 6.2 (1.2-34) 0.033 8.1 (0.8-79) 0.072 
    Karnofsky performance status   25.0 (1.6-333) 0.022 
    Sex   6.7 (0.7-50) 0.082 

NOTE: Covariates included into the analysis are age, sex, Karnofsky performance status, largest tumor diameter, extraocular growth, ciliary body infiltration, PCR, tyrosinase, MelanA/MART1, and time from diagnosis to blood sampling. (A) Model with PCR as combined variable, all patients. (B) Model with tyrosinase and MelanA/MART1 as separate variables, all patients. (C) Model with PCR as combined variable, subgroup of patients with blood sampling at primary local therapy. Forward and backward elimination gave identical results for time to metastases in all models and for DSS in model (B).

*

Tyrosinase or MelanA/MART1.

For disease-specific survival results of backward elimination are shown, in forward elimination age was not in the model.

For disease-specific survival, results of backward elimination are shown, in forward elimination sex was not in the model.

Close Modal

or Create an Account

Close Modal
Close Modal